For decades, India’s life sciences identity has rested on a formidable but ultimately derivative foundation—generics, contract manufacturing, and vaccine production delivered at a scale and cost efficiency that the world has come to rely upon. That foundation remains commercially indispensable. What is shifting, with gathering momentum, is the ambition layered above it.
Biologics and advanced therapeutics—medicines derived from living systems, proteins, cells, and genetic tools rather than chemical synthesis—represent the fastest-growing and highest-value segment of global pharmaceuticals. India’s bioeconomy crossed $165 billion in 2024 and has continued expanding through 2025, whilst the enterprise base has nearly doubled within a few years. The structural question confronting the sector is no longer whether India can participate in biologics—it demonstrably can—but whether it can build the ecosystem depth to originate, scale, and export them on genuinely competitive terms.
The Biosimilars Opportunity: Affordable Innovation at Scale
Biosimilars represent the most immediately accessible rung on the biologics ladder, and India’s position here is stronger than many international observers appreciate. These are not simple copies of existing medicines—they are highly similar versions of approved biologic drugs, developed through rigorous analytical, clinical, and regulatory pathways that demand considerably more scientific sophistication than generic small-molecule manufacturing.
As patents on blockbuster biologics used in oncology, diabetes, autoimmune diseases, and rare disorders continue to expire, the global market for affordable biosimilar alternatives is expanding rapidly, and India’s combination of manufacturing competence, scientific talent, and cost structure places it advantageously within that expansion.
Domestic firms have already launched biosimilar products across oncology, diabetes, and supportive care, bringing treatment costs down in a healthcare environment where out-of-pocket spending remains a significant burden on households across income segments. The access argument is as compelling as the commercial one: biosimilars expand the reach of therapies that would otherwise remain financially out of reach for millions of patients. The pathway forward, however, demands continued regulatory strengthening.
Pharmacovigilance, manufacturing consistency, comparability standards, and alignment with international best practices around interchangeability are not optional refinements—they are the prerequisites for the clinician confidence and market trust upon which a credible biosimilar export proposition depends. India’s regulatory system has made genuine progress; it must now accelerate the pace of that evolution rather than consolidate at the current level.
Advanced Therapeutics: The Frontier Where Original Science Competes
Cell therapies, gene therapies, mRNA platforms, and engineered proteins represent a category of medicine qualitatively different from anything India has previously scaled. Unlike generics—which compete almost entirely on price—advanced therapeutics compete on scientific novelty, clinical value, and platform depth. They redefine treatment possibilities for cancer, rare genetic disorders, and immunological conditions that once offered patients limited options. India is still considerably earlier in this space than the United States or Europe, but the foundational elements are beginning to coalesce in ways that warrant serious attention.
Academic centres and startups are increasingly developing cell and gene therapy platforms for oncology and rare diseases. AI-driven drug discovery tools are improving target identification and molecular design, compressing development timelines in ways that reduce the capital required to reach proof-of-concept. Biomanufacturing capabilities are advancing, which matters enormously because advanced therapeutics require highly controlled production environments where process consistency is inseparable from product quality.
The strategic significance of building capability here extends beyond commercial return: it positions India as a source of original technologies rather than a manufacturer of other nations’ innovations, creating high-skill employment in research, regulatory science, process engineering, and clinical development that generics manufacturing structurally cannot generate.
What the Ecosystem Needs to Deliver on Its Promise
Converting India’s current momentum into durable global competitiveness requires deliberate intervention across several interconnected dimensions. The translation gap between academic discovery and commercially viable product remains the most persistent structural weakness—universities and research institutes need tighter linkages to translational centres, clinical networks, and incubators that can carry early-stage science through the development gauntlet.
Shared infrastructure—bioprocessing hubs, Good Manufacturing Practice facilities, specialised testing laboratories—must be expanded and made genuinely accessible to startups and smaller enterprises whose capital constraints would otherwise exclude them from the biologics arena entirely.
Risk capital presents an equally critical constraint. Biologics and advanced therapeutics are long-horizon investments with substantial failure rates before eventual success; without patient funding that tolerates the development timeline, promising startups will not survive the journey from laboratory to market. Talent pipelines require deliberate broadening beyond traditional biology departments to encompass the cross-disciplinary teams—molecular biologists, process engineers, data scientists, clinical researchers, and regulatory specialists operating in genuine collaboration—that frontier therapeutics demand.
India already possesses manufacturing strength, scientific depth, and a domestic market large enough to anchor initial commercial viability whilst exports scale. The distance between where the country currently stands and genuine global leadership in biologics is not primarily technological. It is institutional—a question of whether industry, academia, and government can sustain the coordinated, long-term commitment that converts a strong foundation into an ecosystem capable of defining the future of medicine rather than merely serving it.